Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Yale Center for Clinical Investigation: leveraging industry partnerships and research cores.

Sherwin R, Slayman C, Rockwell S, Herold K, Williams K, Carson R, Mane S, Seow H, Max J, Johnson T.

Clin Transl Sci. 2012 Dec;5(6):435-6. doi: 10.1111/cts.12016. No abstract available.

2.

Public-private relationships in biobanking: a still underestimated key component of open innovation.

Hofman P, Bréchot C, Zatloukal K, Dagher G, Clément B.

Virchows Arch. 2014 Jan;464(1):3-9. doi: 10.1007/s00428-013-1524-z. Epub 2013 Dec 14. Review.

PMID:
24337181
3.

Public-private partnerships in translational medicine: concepts and practical examples.

Luijten PR, van Dongen GA, Moonen CT, Storm G, Crommelin DJ.

J Control Release. 2012 Jul 20;161(2):416-21. doi: 10.1016/j.jconrel.2012.03.012. Epub 2012 Mar 20. Review.

PMID:
22465390
4.

The Innovative Medicines Initiative moves translational immunology forward.

Goldman M, Wittelsberger A, De Magistris MT.

Eur J Immunol. 2013 Feb;43(2):298-302. Review.

PMID:
23534061
5.

Principles for building public-private partnerships to benefit food safety, nutrition, and health research.

Rowe S, Alexander N, Kretser A, Steele R, Kretsch M, Applebaum R, Clydesdale F, Cummins D, Hentges E, Navia J, Jarvis A, Falci K.

Nutr Rev. 2013 Oct;71(10):682-91. doi: 10.1111/nure.12072. Review.

6.

Leveraging public private partnerships to innovate under challenging budget times.

Portilla LM, Rohrbaugh ML.

Curr Top Med Chem. 2014;14(3):326-9. Review.

7.

Translational research and the evolving landscape for biomedical innovation.

Kaitin KI.

J Investig Med. 2012 Oct;60(7):995-8. doi: 10.2310/JIM.0b013e318268694f. Review.

8.

Pioneering government-sponsored drug repositioning collaborations: progress and learning.

Frail DE, Brady M, Escott KJ, Holt A, Sanganee HJ, Pangalos MN, Watkins C, Wegner CD.

Nat Rev Drug Discov. 2015 Dec;14(12):833-41. doi: 10.1038/nrd4707. Epub 2015 Nov 20. Review.

PMID:
26585533
10.

Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.

Wellenreuther R, Keppler D, Mumberg D, Ziegelbauer K, Lessl M.

Drug Discov Today. 2012 Nov;17(21-22):1242-8. doi: 10.1016/j.drudis.2012.04.004. Epub 2012 Apr 12. Review.

PMID:
22521665
12.

Academic, Foundation, and Industry Collaboration in Finding New Therapies.

Ramsey BW, Nepom GT, Lonial S.

N Engl J Med. 2017 May 4;376(18):1762-1769. doi: 10.1056/NEJMra1612575. Review. No abstract available.

13.

Challenges for pharmaceutical industry: new partnerships for sustainable human health.

Hunter J.

Philos Trans A Math Phys Eng Sci. 2011 May 13;369(1942):1817-25. doi: 10.1098/rsta.2010.0377. Review.

14.

New opportunities and novel paradigms to support neuromuscular research.

Lieber R, Ward S, Frank L, Schenk S.

Phys Med Rehabil Clin N Am. 2012 Feb;23(1):95-105, xi. doi: 10.1016/j.pmr.2011.11.015. Review.

PMID:
22239877
15.

CTSA-IP: a solution to identifying and aggregating intellectual property across the NIH Clinical Translational Science Award (CTSA) consortium of biomedical research institutes.

Hazard M, Steele S, Wang D, Pearson T, Scheideler M, Dewhurst S.

Clin Transl Sci. 2011 Oct;4(5):328-31. doi: 10.1111/j.1752-8062.2011.00308.x. Review. Erratum in: Clin Transl Sci. 2012 Feb;5(1):112.

16.

Public-private collaborations and partnerships in stratified medicine: making sense of new interactions.

Chataway J, Fry C, Marjanovic S, Yaqub O.

N Biotechnol. 2012 Sep 15;29(6):732-40. doi: 10.1016/j.nbt.2012.03.006. Epub 2012 Mar 17. Review.

PMID:
22446473
17.

Academia-industry collaboration: an integral element for building "omic" resources.

Hill DE, Brasch MA, del Campo AA, Doucette-Stamm L, Garrels JI, Glaven J, Hartley JL, Hudson JR Jr, Moore T, Vidal M.

Genome Res. 2004 Oct;14(10B):2010-4. Review. No abstract available.

Supplemental Content

Support Center